GlaxoSmithKline S.A.E (EGX:BIOC)

GlaxoSmithKline S.A.E Balance Sheet

Financials in millions EGP. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	205.35	479.69	75.47	829.34	585.85	73.57
Cash & Short-Term Investments	205.35	479.69	75.47	829.34	585.85	73.57
Cash Growth	-35.27%	535.59%	-90.90%	41.56%	696.36%	232.01%
Accounts Receivable	940.7	768.37	803.28	685.96	424.68	253.94
Other Receivables	42.94	3	50.34	23.89	318.64	408.81
Receivables	1,731	1,693	1,844	1,176	1,165	830.42
Inventory	1,861	1,419	945.21	695.27	485.89	500.45
Prepaid Expenses	-	-	-	-	-	17.58
Other Current Assets	-	-	-	164.7	216.65	126.47
Total Current Assets	3,797	3,592	2,865	2,866	2,454	1,548
Property, Plant & Equipment	848.02	756.84	641.17	572.14	548.11	540.21
Long-Term Investments	543.5	42.63	7.34	6.34	24.45	12.3
Goodwill	-	-	-	-	137.65	238.65
Long-Term Deferred Tax Assets	-	-	23.33	17.43	-	-
Other Long-Term Assets	98.75	109.97	115.83	96.48	21.33	85.09
Total Assets	5,287	4,501	3,653	3,558	3,185	2,425

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	212.43	1,023	486.93	524.53	176.8	104.54
Accrued Expenses	715.59	684.14	577.83	524.12	304.51	581.22
Short-Term Debt	1,746	-	-	-	-	118.21
Current Portion of Leases	42.11	43.79	38.28	28.39	17.48	29.52
Current Income Taxes Payable	25.22	65.51	159.39	97.93	308.57	17.38
Other Current Liabilities	349.51	394.88	313.45	348.98	585.89	161.22
Total Current Liabilities	3,091	2,211	1,576	1,524	1,393	1,012
Long-Term Leases	-	37.97	81.2	68.63	52.07	32.24
Long-Term Deferred Tax Liabilities	14.49	34.43	-	-	11.31	22.46
Total Liabilities	3,105	2,284	1,657	1,593	1,457	1,067

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	835.14	835.14	835.14	835.14	835.14	835.14
Retained Earnings	1,346	1,382	1,160	1,130	892.71	522.24
Total Common Equity	2,181	2,217	1,995	1,965	1,728	1,357
Minority Interest	0.61	0.61	0.6	0.6	0.58	0.58
Shareholders' Equity	2,182	2,217	1,996	1,965	1,728	1,358
Total Liabilities & Equity	5,287	4,501	3,653	3,558	3,185	2,425

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	1,788	81.76	119.48	97.03	69.55	179.97
Net Cash (Debt)	-1,583	397.93	-44.01	732.32	516.3	-106.41
Net Cash Growth	-	-	-	41.84%	-	-
Net Cash Per Share	-18.95	4.76	-0.53	8.77	6.18	-1.27
Filing Date Shares Outstanding	83.51	83.51	83.51	83.51	83.51	83.51
Total Common Shares Outstanding	83.51	83.51	83.51	83.51	83.51	83.51
Working Capital	706.1	1,380	1,289	1,342	1,060	536.41
Book Value Per Share	26.12	26.54	23.89	23.53	20.69	16.25
Tangible Book Value	2,181	2,217	1,995	1,965	1,590	1,119
Tangible Book Value Per Share	26.12	26.54	23.89	23.53	19.04	13.40
Land	-	17.59	17.59	17.59	12.65	12.65
Buildings	-	65.48	74.34	83.47	97.81	97.81
Machinery	-	811.29	696.44	668.83	662.18	629.59
Construction In Progress	313.02	197.12	152.54	108.51	88.86	98.67
Leasehold Improvements	-	35.38	24.27	26.81	26.85	42.34

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 21, 2026

Data Sources Report a data error